Skip to main content
main-content

13-06-2020 | Haematology | Video

EHA25 | Triplet immunotherapy-based regimen shows promise for relapsed, refractory DLBCL

Charles Herbaux presents the primary analysis of the phase 2 GATA study showing the potential of combining atezolizumab, obinutuzumab and venetoclax for the treatment of relapsed or refractory diffuse large B-cell lymphoma (5:11).

Funding for independent interviews at EHA25 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Image Credits